cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gt Biopharma Inc
6 own
5 watching
Current Price
$3.2
$0.39
(13.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10.34M
52-Week High
52-Week High
10.66000
52-Week Low
52-Week Low
1.72000
Average Volume
Average Volume
0.65M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization10.34M
icon52-Week High10.66000
icon52-Week Low1.72000
iconAverage Volume0.65M
iconDividend Yield--
iconP/E Ratio--
What does the Gt Biopharma Inc do?
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Read More
How much money does Gt Biopharma Inc make?
News & Events about Gt Biopharma Inc.
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer (NK) cell engager, TriKE platform, has named Charles J. ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced that Dr. Jeffrey ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, issued an open ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced ...
Globe Newswire
2years ago
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at...
Frequently Asked Questions
Frequently Asked Questions
What is Gt Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Gt Biopharma Inc shares?
plus_minus_icon
How can I buy Gt Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Gt Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gt Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Gt Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Gt Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gt Biopharma Inc?
plus_minus_icon
What percentage is Gt Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gt Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.2
$0.39
(13.88%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00